Skip to main content
Caplight Logo









GenomaA Biotech

GenomaA Biotech

Private
PiracicabaHealthcare & Life Scienceshttps://genomaa.com.br/pt-br

Momentum

Top 50%

of companies Caplight tracks

Company Overview

GenomaA Biotech operates in Healthcare & Life Sciences and is based in Piracicaba. It was founded in 2020.

GenomaA Biotech is a biotechnology company that provides molecular biology services, including genetic sequencing and DNA species identification for the agribusiness, environmental, and industrial sectors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Environmental Monitoring, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

GenomaA Biotech Comparables

Compare GenomaA Biotech with similar companies based on industry and business-model similarity.

GenomaA Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MetaGen Soluções Moleculares
88%
GoGenetic
86%
B4A
83%
Book a demo to see all comparables

For institutional investors. Book with your work email.

GenomaA Biotech Funding Rounds

Historical fundraising activity

Funding history

No completed funding rounds are published for GenomaA Biotech. Book a demo to ask about coverage.

Book a demo

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors grew 159% MoM, reaching 2.5K.

  • Apr 20, 2026

    Monthly visitors increased 303% MoM.

Book a demo to see all signals

For institutional investors. Book with your work email.

GenomaA Biotech Filings

Explore SEC and related filing metadata, where available.

GenomaA Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about GenomaA Biotech's valuation, stock price, and market status.

Is GenomaA Biotech a public or private company?

GenomaA Biotech is a private company.

What is the current stock price of GenomaA Biotech?

GenomaA Biotech is a private company, so its shares have no public market price. Caplight tracks GenomaA Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is GenomaA Biotech worth (valuation)?

Valuation information for GenomaA Biotech is not publicly available.

Can I buy GenomaA Biotech stock?

GenomaA Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was GenomaA Biotech's last funding round?

Funding round information for GenomaA Biotech is not publicly available.

Who are the main investors in GenomaA Biotech?

Investor information for GenomaA Biotech is not publicly disclosed.

Will GenomaA Biotech IPO soon?

No public IPO plans have been announced for GenomaA Biotech.

How can I track GenomaA Biotech secondary market activity?

Caplight tracks bids, offers, and trades in GenomaA Biotech's shares on secondary markets.

Firmographic Details

HeadquartersPiracicaba
Employee Range5
Year Founded2020
Last Funding—

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?